UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Late relapse of osteosarcoma: Implications for follow-up and screening

Strauss, SJ; McTiernan, A; Whelan, JS; (2004) Late relapse of osteosarcoma: Implications for follow-up and screening. PEDIATR BLOOD CANCER , 43 (6) 692 - 697. 10.1002/pbc.20154.

Full text not available from this repository.

Abstract

Long-term disease-free survival in patients with localised osteosarcoma treated in large multicentre randomised trials is over 50%. Most relapses occur early, usually within 2-3 years. Relapse after 5 years is uncommon and has been infrequently described. Eight patients with osteosarcoma treated at The London Bone and Soft Tissue Tumour Service since 1986 developed recurrence of disease after 5 years, the latest 14 years after the initial diagnosis. Five patients developed pulmonary metastases, two patients isolated bone metastases and one patient intra-abdominal metastases. Although a second complete remission was achieved in six patients, four patients relapsed again, all with pulmonary metastases. Two patients had coexistent brain metastases. one of those with a second recurrence has achieved a further complete remission and remains well 50 months after the most recent treatment. A second patient is disease-free 24 months after complete excision of an isolated pulmonary metastasis and one further patient is disease-free 6 months after chemotherapy and pneumonectomy for pleural and pulmonary metastases. Five patients have died of disease with a median survival from the date of relapse of 17 months (2-68 months). Current data looking at long-term outcome of patients with osteosarcoma is limited. Reports of late relapse are rare as numbers are small, thus long-term surveillance of patients is essential. It is possible that sites of relapse are more unusual, and more extensive staging may be necessary when late relapse occurs. (C) 2004 Wiley-Liss, Inc.

Type: Article
Title: Late relapse of osteosarcoma: Implications for follow-up and screening
DOI: 10.1002/pbc.20154
Keywords: follow-up, late relapse, osteosarcoma, ADJUVANT CHEMOTHERAPY, METASTATIC OSTEOSARCOMA, OPERABLE OSTEOSARCOMA, PULMONARY METASTASES, PROGNOSTIC-FACTORS, PHASE-II, INTERGROUP, EXTREMITY, SURVIVAL, TRIAL
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/71601
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item